Licensing Analysis
🇪🇺 EMAExpert commentary and market intelligence for pharma strategy teams
Showing 1–3 of 3 articles
Earlier
Medium impact AnalysisMay 28, 2026
Viridian Partners with WuXi Bio for Eye Drug Supply Amid FDA Decision
FDA · 4 min
Dr. Elena RossiHigh impact AnalysisMay 21, 2026
Gilead's $140M Deal with Yuhan: Implications for Pharma
2 min
Dr. Elena RossiHigh impact AnalysisMay 21, 2026
Roche's Licensing Deal for Xofluza: Implications and Insights
3 min
Dr. Elena RossiExplore intelligence